Clinical Trials
Open
Phase
Accrual
99%
SWOG Clinical Trial Number
S1904
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Status Notes
This study is approaching the overall accrual target, therefore, it will be permanently closed to new patient accrual, effective June 14, 2024, at 12:00 p.m. PT.
Research Committee(s)
Prevention & Epidemiology
Breast Cancer
Activated
09-01-2020
ClinicalTrials.gov Registry Number
NCT 04496739
Open
Phase
Accrual
28%
SWOG Clinical Trial Number
S1905
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Status Notes
Re-opened to accrual effective: 10/02/2023.
Research Committee(s)
Leukemia
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT#04315324
Open
Phase
Accrual
83%
SWOG Clinical Trial Number
S1933
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
Status Notes
This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
NCT04310020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1929
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)
Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.
Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
Closed
12-15-2022
ClinicalTrials.gov Registry Number
04334941
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1823
A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors
Status Notes
This study was permanently closed to new patient accrual, effective May 20, 2024. This closure does not affect enrolled patients. Submission of specimens and data continue per protocol.
Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06-01-2020
Open
Phase
Accrual
87%
SWOG Clinical Trial Number
S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
Status Notes
This study is open to accrual effective March 25, 2020.
Research Committee(s)
Lung Cancer
Activated
03-25-2020
ClinicalTrials.gov Registry Number
04214262
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
S1900B
A PHASE II STUDY OF SELPERCATINIB (LOXO-292) IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
S1900B will close to accrual April 30, 2021, effective 12:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-10-2020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1900C
A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)
Status Notes
S1900C closed to accrual December 18, 2020.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-16-2020
Closed
12-18-2020
Open
Phase
Accrual
37%
SWOG Clinical Trial Number
S1827
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Status Notes
This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
01-10-2020
ClinicalTrials.gov Registry Number
04155034
Open
Phase
Accrual
74%
SWOG Clinical Trial Number
S1922
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Status Notes
Permanently closed to accrual, effective December 01, 2022, 12:00 p.m. Pacific Time
Research Committee(s)
Lymphoma
Activated
07-19-2019
Closed
12-01-2022
ClinicalTrials.gov Registry Number
03907488
Open
Phase
Accrual
100%
SWOG Clinical Trial Number
S1803
Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Status Notes
This study is re-opened to patient accrual effective 11/15/2023.
Research Committee(s)
Myeloma
Activated
06-27-2019
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S1916
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer Patients
Status Notes
This study is permanently closed effective September 16, 2020.
Research Committee(s)
Cancer Care Delivery
Activated
06-11-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1800A
A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Status Notes
S1800A closed to accrual November 16, 2020.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
05-17-2019
Closed
11-16-2020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Status Notes
Study permanently closed to accrual as of 04/01/2024, noon PST.
Research Committee(s)
Genitourinary Cancer
Activated
04-19-2019
Closed
04-01-2024
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1714
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Status Notes
S1714 will permanently close to accrual on November 15, 2021 at 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03-01-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1600
A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Status Notes
S1600 study will be permanently closed to accrual, effective 10/20/2023.
Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02-21-2019
Closed
10-20-2023
ClinicalTrials.gov Registry Number
NCT03757949
Closed
Phase
Accrual
1%
SWOG Clinical Trial Number
S1614
Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Cytotoxic Therapy for Solid Tumors
Status Notes
Active 2/21/19
Reactivation, effective 7/1/21
Reactivation, effective 7/1/21
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
02-21-2019
Closed
11-15-2022
ClinicalTrials.gov Registry Number
03887702
Closed
Phase
Accrual
73%
SWOG Clinical Trial Number
S1900A
A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA 1/2 MUTATION STAGE IV NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
Status Notes
S1900A is permanently closed to accrual, effective 2/1/21.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-29-2019
ClinicalTrials.gov Registry Number
NCT03845296
Open
Phase
SWOG Clinical Trial Number
LUNGMAP
A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Status Notes
LUNGMAP will open to accrual January 28, 2019, effective 2:00 pm PST.
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
01-28-2019
ClinicalTrials.gov Registry Number
NCT03851445